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Introduction
Prostate cancer (PCa) is the most common type of cancer in American men and the second leading cause of cancer mortality (1). Following surgery or radiation, the standard treatment for hormone-sensitive PCa is continuous androgen deprivation therapy (ADT) at the maximum tolerable dose (MTD) with or without continuous abiraterone acetate (AA) until the tumor becomes castration resistant (2) . Importantly, advanced PCa is not curable because PCa routinely evolves resistance to all current treatment modalities. Continuous treatment approaches fail to consider the evolutionary dynamics of treatment response where competition, adaptation and selection between treatment sensitive and resistant cells contribute to therapy failure (3) . In fact, continuous treatment, by maximally selecting for resistant phenotypes and eliminating other competing populations, may actually accelerate the emergence of resistant populations -a wellstudied evolutionary phenomenon termed "competitive release".
In part to address this issue, prior trials have used intermittent ADT (IADT) to reduce toxicity and delay time to progression (TTP). However, these trials were typically not designed with a detailed understanding of the underlying evolutionary dynamics. For example, a prospective Phase II trial of IADT for advanced PCa included an 8-month induction period in which the patients were treated at MTD prior to beginning intermittent therapy (4) . We have previously postulated that only a small number of ADT-sensitive cells would typically remain after the induction period, thereby significantly reducing the potential of intermittent treatment to take advantage of the evolutionary dynamics (3) .
Fully harnessing the potential of intermittent PCa therapy requires identifying ADT resistance mechanisms, predicting individual responses, and determining potentially highly patient-specific, clinically actionable triggers for pausing and resuming IADT cycles. Progress in integrated mathematical oncology may make such analysis possible. Many mathematical models based on a variety of plausible resistance mechanisms have been proposed to simulate IADT responses (3, (5) (6) (7) (8) (9) (10) (11) (12) (13) . While these models can fit clinical data, they often rely on numerous model variables and parameters that in combination fail to adequately predict responses and outcomes for individual patients (9) . We hypothesize that prostate cancer stem cells (PCaSCs) may be, at least in part, responsible for tumor heterogeneity and treatment failure due to their self-renewing, differentiating and quiescent nature (14) (15) (16) . Simulating longitudinal prostate-specific antigen (PSA) levels in early IADT treatment cycles could help identify patient-specific PCaSC dynamics to computationally forecast individual disease dynamics and reliably predict IADT response or resistance in subsequent treatment cycles.
The first evidence of stem cells in the prostate was provided by Isaacs and Coffey (17) , who used androgen cycling experiments in rodents to show that castration resulted in involution of the prostate, while restored androgen levels resulted in complete regeneration of the prostate.
These findings demonstrated that normal prostate depends on androgens for maintenance. A small population of androgen-independent stem cells within the prostate epithelium divide to give rise to amplifying cells, which do not directly depend on androgen for their continuous maintenance but respond to androgens by generating androgen-dependent transit cells.
Approximately 0.1% of cells in prostate tumors express the stem cell markers CD44 + / 2 1 hi /CD133 + (18) , and mice as well as patients treated with ADT have significantly increased
PCaSC populations (19, 20) . This suggests that evolution of or selection for pre-existing androgen-independent PCaSCs contributes to treatment resistance.
The purpose of this study is to evaluate individual PSA dynamics in early IADT treatment cycles as a predictive marker of response or resistance in subsequent treatment cycles.
We hypothesize that patient-specific PCaSC division patterns underlie the measurable 
Materials and Methods

IADT Clinical Trial data
The Bruchovsky prospective Phase II study trial was conducted in 109 men with biochemically recurrent prostate cancer (21) . IADT consisted of 4 weeks of Androcur as lead-in therapy, followed by a combination of Lupron and Androcur, for a total of 36 weeks. Treatment was paused if PSA has normalized (< 4 g/L) at both 24 and 32 weeks, and resumed when PSA increased above 10 g/L. PSA was measured every four weeks. Patients whose PSA had not normalized after both 24 and 32 weeks of being on treatment were classified as resistant and taken off of the study. We analyzed the data of 79 patients who had completed more than one IADT cycle. One patient was omitted for inconsistent treatment, seven were omitted due to the development of metastasis and/or local progression, and one was omitted due to taking multiple medications throughout the trial, resulting in 70 patients included in the analysis (Fig. S1) 
Mathematical Model of IADT Response
We developed a mathematical model of PCaSC (S), non-stem (differentiated) cells (D), and serum PSA concentration (P) (Fig. S2 ). PCaSCs divide with rate (day -1 ) to produce either a PCaSC and a non-stem PCa cell with rate 1-ps (asymmetric division) or two PCaSCs at rate ps (symmetric division) with negative feedback from differentiated cells (15) . Differentiated cells exclusively produce PSA at rate ( g/L day -1), which decays at rate (day
). Unlike androgenindependent PCaSCs, differentiated cells die in response to androgen removal at rate (day -1 ) (33) . IADT on and off cycles are described with parameter Tx, where Tx = 1 when IADT is given and Tx = 0 during treatment holidays.
The coupled mathematical equations describing these interactions are shown below.
Mathematical Model Training and Validation
We assume uninhibited PCaSCs divide on average once per day and set = ln(2). To reduce model complexity and prediction uncertainty, we assume PSA production rate ( ) and decay rate ( ) to be uniform between patients. PCaSC self-renewal rate (ps) and differentiated cell ADT sensitivity ( ) are correlated and assumed to be patient-specific. We used particle swarming optimization (PSO) (34) to identify population uniform and patient-specific model parameters that minimize the least squares error between model simulation and patient data in the training cohort. The trained mathematical model is assessed for accuracy in the validation cohort. The learned population uniform parameters are kept constant for all patients, and PSO is performed to find appropriate values for ps and to produce accurate data fits.
Adaptive Bayesian Response Prediction
In order to predict the evolution of resistance, we started by fitting the model to each cycle of the training cohort data individually. That is, finding the optimal values of ps and , while allowing and to remain fixed at the values previously found, to fit one cycle of data at a time (Fig.   S3A ). We then measured the relative change in ps between cycles and used this to generate cumulative probability distributions as shown in Fig. S3B . Sampling from the 95% confidence interval around the exponential curve relating ps to in cycle i+1 (Fig. S3C) , we found a corresponding i+1. This ps,i+1 and i+1 were used to predict the response in cycle i+1. This process was repeated 1000 times to generate 1000 predictions. In line with the trial by Bruchovsky et al. (21) , resistance was defined as PSA increasing during treatment and/or a PSA level above 4 g/L at both 24 and 32 weeks after the start of a cycle of treatment. Simulations that satisfied either of these conditions were classified as resistant. Thus, for each cycle prediction we obtained a probability of resistance (P(Ω) = number of resistance predictions out of 1000 simulations).
To determine whether to categorize a patient as responsive or resistant based on our predictions, we used the results from the training cohort data to find a cycle-specific threshold i for each cycle (Fig. S3D ). If P(Ω)> i, then the patient was predicted as resistant in cycle i. For each cycle, a value of was chosen that would maximize the sensitivity (predicting resistance when a patient is indeed resistant), and specificity (predicting resistance when a patient is actually responsive) of the training cohort. Each resistance threshold was used to predict response or resistance in the training cohort.
Modeling concurrent docetaxel
Unlike ADT, docetaxel can induce cell death in both PCaSCs and non-stem cells, though to a lesser degree in PCaSCs compared to non-stem cells (35) . To model this, we extended the current model to include death of each cell type at rates = (day -1 ) and > (day -1 ). That is,
where TxD = 1 when docetaxel is on and TxD = 0 otherwise. Each cycle of docetaxel was simulated as a single dose on day n (TxD = 1) followed by three weeks without docetaxel (TxD = 0). The parameters = = 0.0027 and > = 0.008 were chosen such that approximately three times more non-stem cells died than PCaSCs (35) .
Results
Mathematical model accurately simulates patient-specific IADT response dynamics
The model was calibrated to and assessed for accuracy on longitudinal data from a prospective Fig. S4D ). As shown in Fig. S4D , analysis revealed an exponential relationship between ps and and therefore these parameters are not independent. This relationship allows prediction of future cycles based on PCaSC self-renewal rate ps as the single, identifiable, independent patient-specific parameter.
To assess the accuracy of our model, we set the PSA production rate and decay rate to the values obtained from the training cohort and identified patient-specific values for ps and corresponding in the testing cohort. With these, the model was able to fit the data equally well (R 2 =0.69) and the resulting parameter distributions and relationships were similar to those found in the training cohort ( Fig. 1A-D) .
PCaSC self-renewal rates underlying observable PSA dynamics can predict subsequent IADT cycle responses
To predict the evolution of resistance in subsequent treatment cycles, we fit the model to single treatment cycles for patients in the training set, again setting the PSA production rate and decay rate to the values previously found. The self-renewal and ADT cytotoxicity rates 
IADT without induction period significantly increases TTP
In a study by Crook et al., continuous ADT was compared to IADT in localized PCa patients and they found that IADT was non-inferior to ADT using overall survival as the clinical endpoint (4). ADT showed that IADT with an induction period resulted in significantly longer TTP ( Fig. 2A) .
Though median TTP was not reached for either IADT protocol, Fig. 2B shows that the average TTP was approximately 5 months longer for IADT without the induction period when compared to the actual trial data and the continuous ADT simulations. Fig. 2C shows TTP could be increased by more than 7 months in selected patients.
Alternative treatment decision thresholds can further increase TTP
In the ongoing pilot study (NCT02415621) of IADT in metastatic, castration resistant PCa patients, IADT is paused after a decline in PSA to below 50% of pre-treatment PSA levels and is resumed once PSA returns to the pre-treatment level. At the time of writing, of the 18 patients currently enrolled for more than 12 months, four have developed PSA and radiographic progression. The median time to progression has not been reached, but is at least 20 months greater than a contemporaneous cohort treated continuously with MTD until progression, as well as published cohorts. The treatment group has received an average cumulative dose of less than half that of standard of care treatment (3).
To test the validity of our model, we simulated IADT using a 50% threshold, as well as 10% and 70% and compared the results against those obtained in the Bruchovsky trial. Pausing treatment once PSA falls below 70% and 10% of the pre-treatment PSA, checking every two weeks, results in significantly longer TTP when compared to the Bruchovsky trial protocol (Fig.   3) . Additionally, the average cumulative dose could be significantly reduced depending on the threshold used. With a 10% threshold, the average cumulative dose is ~50% of that of the Bruchovsky study. A 50% threshold results in ~22% of the cumulative dose used in the Bruchovsky study, while 70% results in ~20%. Controlling for the total time that each patient participated in the trial results in about 30%, 15%, and 13% of the comulative dose used in the Bruchovsky study for thresholds of 10%, 50%, and 70%, respectively (Fig. S5) .
Concurrent docetaxel administration provides favorable TTP
We sought to investigate the effect of docetaxel (DOC) in IADT in biochemically recurrent PCa patients by simulating six cycles of DOC with concurrent ADT, followed by IADT (as defined in the Materials and Methods section). Model analysis showed that patients with higher stem cell self-renewal rates would benefit the most from DOC in a castration naïve setting (prior to progression, Fig. 4A ). Comparing progression free survival showed that castration naïve docetaxel could increase TTP (Fig. 4B) . We also tested the ability of DOC to increase survival after the development of resistance to IADT. To do this, we simulated IADT, following the Bruchovsky trial protocol, and then added ten cycles of DOC plus continuous ADT after resistance developed. As shown in Fig. 4C , this increased mean TTP from 41.18 months observed in the Bruchovsky trial to model-predicted 50.14 months.
First cycle PCaSC self-renewal rate stratifies patients who can benefit from docetaxel
As shown above, the stem cell self-renewal rate plays a significant role in IADT and could accurately predict a patient's response in subsequent cycles after just the first cycle. With this, we used the first cycle ps value to simulate six cycles of DOC with concurrent ADT followed by IADT and found that patients with ps ≥ med(ps) could benefit from DOC after the first cycle of IADT (Fig. 5A) . There was a significant difference in TTP between patients with a high ps and those with a low ps both when simulating IADT with and without DOC after the first cycle (Fig.   5B ). Though the difference in TTP was not significantly higher with DOC given after the first cycle ( Our study also demonstrated the value of ongoing model simulations in predicting outcomes from each treatment cycle throughout the course of therapy. By accumulating data from each cycle to continuously estimate the current tumor population dynamics, model simulations could predict the response to the next cycle with a sensitivity and specificity of 57% and 94%, respectively and an overall accuracy of 90%. This ability to learn from prior treatments and predict future outcomes adds an important degree of flexibility to a cancer treatment protocol-a game theoretic strategy termed "Bellman's Principle of Optimality" that greatly increases the physician's advantage (25) .
For those predicted to become resistant in the next cycle of IADT, an ideal model would also predict alternative treatments that could produce better clinical outcomes. The role of docetaxel in metastatic, hormone-sensitive PCa has been investigated in three studies in the past five years. The GETUG-AFU15 study found a non-significant 20% increase in overall survival in high volume disease (HVD) patients who received DOC concurrently with continuous ADT, but no survival benefit in those with low volume disease (LVD) (26) . Subsequently, the results of the STAMPEDE trial found that DOC administration resulted in a more than 12 months overall survival benefit with a median follow-up of 43 months (27) . Finally, the CHAARTED trial showed a statistically significant overall survival benefit from adding DOC in patients with HVD; however, no statistically significant survival benefit was found in LVD patients (28).
Here we explored the option of adding docetaxel in the treatment of biochemically recurrent PCa. We found that estimating the PCaSC self-renewal rate ps using data from the first cycle of IADT could stratify patients who would receive the most benefit from concurrent administration of docetaxel. These results emphasize the critical heterogeneity within patients that affect response to therapy and the important role of quantitative models in identifying patient-specific parameters and defining appropriate treatment protocols based on model predictions.
Our study has some limitations in both the clinical data set and quantitative models.
Since only 21% of the 70 patients progressed before the conclusion of the trial (21) (Fig. S1) , the clinical data included more responsive than resistant patients in both the training and testing In conclusion, our study demonstrates that a simple mathematical model based on cellular dynamics in prostate cancer can have a high predictive power in a retrospective data set from patients with biochemically recurrent PCa undergoing IADT.
In particular, we demonstrate the model can use data from each treatment cycle to estimate intratumoral subpopulations and accurately predict the outcome of subsequent cycles. Furthermore, in patients who are predicted to fail therapy in the next cycle, alternative treatments for which a response is more likely can be predicted. We conclude that PSA dynamics can prospectively predict treatment response to IADT, suggesting ways to adapt treatment to delay TTP. On the trial protocol, the patient became resistant after 1384 days. With a threshold of 10%, resistance could be delayed for 1554 days. With a threshold of 50% and 70%, the patient could continue on the protocol for more than 3600 days. 
